The agreement provides AstraZeneca with a global license for all uses of the compounds, as well as exclusive manufacturing and commercial rights. It also establishes a research collaboration that will focus on jointly generating additional novel triple reuptake inhibitor (TRI) compounds. Financial details were not disclosed.
Christer Kohler, vice president for AstraZeneca’s global discovery research area focused on central nervous system & pain, said: “Besides enabling us to harness the combined power of two institutions, this agreement also establishes a strong footing for AstraZeneca in the strategically important TRI research area.
“We continue to build alliances and collaborations within the scientific community and this deal is another example of our strong commitment and ability to leverage innovation with the aim of making a meaningful difference in patients’ lives.”